<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2016-03-14</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001105533</issuerCik>
        <issuerName>ARGOS THERAPEUTICS INC</issuerName>
        <issuerTradingSymbol>ARGS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001669166</rptOwnerCik>
            <rptOwnerName>ForArgos B.V.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O FORBION CAPITAL PARTNERS</rptOwnerStreet1>
            <rptOwnerStreet2>GOOMIEER 2-35</rptOwnerStreet2>
            <rptOwnerCity>1411 DC NAARDEN</rptOwnerCity>
            <rptOwnerState>P7</rptOwnerState>
            <rptOwnerZipCode></rptOwnerZipCode>
            <rptOwnerStateDescription>NETHERLANDS</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>881745</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Common Stock Warrant (right to buy)</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>5.35</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2016-03-14</value>
            </exerciseDate>
            <expirationDate>
                <value>2021-03-14</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>661309</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The reported securities are included within Units purchased by the Reporting Person for $5.44375 per Unit.  Each Unit consists of one share of common stock and one warrant to purchase 0.75 shares of common stock.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>By Forbion 1 Management B.V. as Director of ForArgos B.V., /s/ M.A. van Osch</signatureName>
        <signatureDate>2016-03-16</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>By Forbion 1 Management B.V. as Director of ForArgos B.V., /s/ G.J. Mulder</signatureName>
        <signatureDate>2016-03-16</signatureDate>
    </ownerSignature>
</ownershipDocument>
